Dr. Andre Boulet reports

DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING

In connection with an evaluation of an additional listing of Devonian Health Group Inc.'s common shares on a U.S. stock exchange, following the approval of its shareholders by a majority of 99.79 per cent, the company will be implementing a consolidation (reverse stock split) of its outstanding common shares on the basis of one new common share for every 60 currently outstanding common shares.

The company believes that the increase to the trading price of the common shares from effecting the consolidation could potentially and principally: (i) broaden the pool of investors that may consider investing or be able to invest in the company; and (ii) enable the company to satisfy certain minimum trading price requirements of U.S. and other stock exchanges for a potential listing of the common shares.

The consolidation ratio was determined by the company's board of directors and the officers of the company in accordance with the parameters authorized by the company's shareholders at the company's annual and special meeting of the shareholders held on March 20, 2025. The consolidation is subject to final acceptance of the TSX Venture Exchange. The company intends to complete the consolidation at the open of market on or around Jan. 22, 2026, and the common shares are expected to commence trading on the TSX-V on a postconsolidation basis beginning at the open of markets on or around Jan. 22, 2026, under the existing name and symbol (GSD). On the OTCQB Venture Market, the company's trading symbol will also remain unchanged, although a "D" will be temporarily appended as the fifth character of the trading symbol for 20 business days starting the effective date of the consolidation. Following the consolidation, the new Cusip number for the common shares will be 251834883 and the new ISIN (international securities identification number) will be CA2518348834.

The company currently has 165,943,512 common shares issued and outstanding, and, upon completion of the consolidation, the company expects to have approximately 2,765,725 common shares issued and outstanding, subject to any issuances prior to the consolidation and rounding for any fractional shares. No fractional shares will be issued as a result of the consolidation and the number of postconsolidation shares to be received by each shareholder will be rounded to the nearest whole common share that such holder would otherwise be entitled to receive upon the implementation of the share consolidation.

Holders of common shares who hold uncertificated shares (that is shares held in book-entry form and not represented by a physical share certificate), either as registered holders or beneficial owners, will have their existing book-entry account(s) electronically adjusted by the company's transfer agent or, for beneficial shareholders, by their brokerage firm, banks, trusts or other nominees that hold in street name for their benefit. Such holders do not need to take any additional actions to exchange their preconsolidation common shares for postconsolidation common shares. If you hold your common shares with such brokerage firm, bank, trust or other nominee and if you have questions in this regard, you are encouraged to contact your nominee.

Registered shareholders holding share certificates will be mailed a letter of transmittal advising of the share consolidation and instructing them to surrender their share certificates representing preconsolidation common shares for replacement certificates or a direct registration advice representing their postconsolidation common shares. Following the effective date of the consolidation and until surrendered for exchange, each share certificate formerly representing preconsolidation common shares will be deemed to represent the number of whole postconsolidation common shares to which the holder is entitled as a result of the consolidation.

About Devonian Health Group Inc.

Devonian Health Group is a clinical-stage pharmaceutical company specializing in the development of drugs for various autoimmune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases, including, but not limited to, atopic dermatitis, radiodermatitis and ulcerative colitis.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licences from brand-name pharmaceutical companies.

Devonian Health Group was incorporated in 2015 and is headquartered in Quebec, Canada, where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX-V (symbol: GSD) and currently quoted on the OTCQB Venture Market (symbol: DVHGF).

We seek Safe Harbor.